Tumor-treating fields is an anti-mitotic treatment modality.It delivers low-intensity alternating electric fields to the tumor and interferes with glioblastoma cell division and organelle assembly. In the study by Roger Stupp et al, patients were randomized into two groups: Tumor-treating fields plus maintenance temozolomide chemotherapy (n=466) or temozolomide alone (n=229).
Tumor treating fields consist of low-intensity, 200 kHz frequency, alternating electric fields.It was delivered for 18 hours/d via 4 transducer arrays on scalp after removal of hairs and connected to a portable device. Temozolomide was administered to both groups (150-200 mg/m2) for 5 days per 28-day cycle (6-12 cycles).
Study concluded that patients with glioblastoma who had received standard radio-chemotherapy, the addition of Tumor-treating fields to maintenance temozolomide chemotherapy resulted in statistically significant improvement in progression-free survival(6.7 vs 4 moths) and overall survival (20.9 vs 16 months.)
Glioblastoma are rapidly growing tumors arising from astrocytes and represents about 15.4% of all primary brain tumors and about 60-75% of all astrocytomas.
For adults with more aggressive glioblastoma, treated with concurrent temozolamide and radiation therapy, median survival is about 14.6 months and two-year survival is 30%.5-year survival rate of ~4%.
Image source: Novocure